

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Intronn Inc.	09/20/2007

RECEIVING PARTY DATA

Name:	VIRXSYS CORPORATION
Street Address:	200 PERRY PARKWAY
Internal Address:	SUITE 1A
City:	GAITHERSBURG
State/Country:	MARYLAND
Postal Code:	20877

PROPERTY NUMBERS Total: 34

Property Type	Number
Application Number:	10434727
Application Number:	09756095
Application Number:	09838858
Application Number:	10076248
Application Number:	10075028
Application Number:	10456273
Application Number:	10693192
Application Number:	10898748
Application Number:	11040634
Application Number:	11041155
Application Number:	10198447
Application Number:	09756097
Application Number:	10621867
Application Number:	60600045

PATENT

500392093

REEL: 020074 FRAME: 0136

CH \$1360.00 10434727

Application Number:	60592607
Application Number:	09133717
Application Number:	09158863
Application Number:	10456153
Application Number:	09087233
Application Number:	09766354
Application Number:	09756096
Application Number:	10658617
Application Number:	10103294
Application Number:	10136723
Application Number:	09941492
Application Number:	11141447
Application Number:	11193682
Application Number:	11199917
Application Number:	11245835
Application Number:	60617012
Application Number:	60629821
Application Number:	60617324
Application Number:	05036424
Application Number:	11245907

CORRESPONDENCE DATA

Fax Number: (410)332-8186
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 4103328685
Email: kkatcheves@saul.com
Correspondent Name: KONSTANTINA M. KATCHEVES
Address Line 1: 500 East Pratt Street, 9th Floor
Address Line 2: Saul Ewing LLP
Address Line 4: Baltimore, MARYLAND 21202

ATTORNEY DOCKET NUMBER:	356007.00001
NAME OF SUBMITTER:	Konstantina M. Katcheves

Total Attachments: 18
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page1.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page2.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page3.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page4.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page5.tif

source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page6.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page7.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page8.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page9.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page10.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page11.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page12.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page13.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page14.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page15.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page16.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page17.tif
source=Intronn IP Assignment containing Exhibit 2-1a 9-20-07#page18.tif

ACQUIRED INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

THIS ACQUIRED INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT (the "*Agreement*") is made and entered into as of September 20, 2007 (the "*Effective Date*") by and among VIRxSYS Corporation, a Delaware corporation ("*Assignee*"), and Intronn Inc., a Delaware corporation ("*Assignor*").

RECITALS

WHEREAS, Assignee and Assignor are parties to that certain Asset Purchase Agreement dated of even date herewith (the "*Asset Purchase Agreement*");

WHEREAS, capitalized terms not defined herein shall have the meanings ascribed to them in the Asset Purchase Agreement; and

WHEREAS, Assignee desires to acquire from Assignor all of Assignor's right, title and interest in the Intellectual Property set forth on Schedule 2.1(a) of the Asset Purchase Agreement attached hereto and incorporated herein by reference.

NOW, THEREFORE, for good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the parties agree as follows:

AGREEMENT

1. Assignment.

1.1 Assignor hereby irrevocably assigns, conveys, otherwise transfers and agrees to transfer to Assignee, and its respective successors and assigns, all right, title and interest worldwide in and to the Acquired Intellectual Property, including but not limited to that Acquired Intellectual Property identified and described in Schedule 2.1(a) of the Asset Purchase Agreement, attached hereto and incorporated herein for all purposes, and all proprietary rights therein, including, without limitation, all issued patents, reissued or reexamined patents, revivals of patents, utility models, certificates of invention, registrations of patents and extensions thereof, regardless of country or formal name, all published or unpublished nonprovisional and provisional patent applications, reexamination proceedings, invention disclosures and records of invention, all copyrights, copyrightable works, including all rights of authorship, use, publication, reproduction, distribution, performance transformation, moral rights and rights of ownership of copyrightable works, and all rights to register and obtain renewals and extensions of registrations, together with all other interests accruing by reason of international copyright, trademarks, registered trademarks, applications for registration of trademarks, service marks, registered service marks, applications for registration of service marks, trade names, registered trade names and applications for registrations of trade names and domain name registrations, all technical information, discoveries, inventions, designs, processes, formulae, know-how, trade secrets, procedures, compositions, methods, protocols, techniques, data, specification and developments and all other intangible assets, properties and rights (whether or not appropriate steps have been taken to protect, under applicable law, such other intangible assets, properties or rights).

1.2 If Assignor has any rights to the Acquired Intellectual Property that cannot be assigned as described above including, without limitation, any moral rights or the equivalent thereof, Assignor agrees to waive enforcement world-wide of such rights against Assignee, its officers, directors, stockholders, agents and employees. If Assignor has any rights to the Acquired Intellectual Property that cannot be assigned or waived as described above, Assignor hereby grants and agrees to grant to Assignee

an exclusive, irrevocable, fully paid-up, and royalty free license, in perpetuity and world-wide, to fully exercise such rights, including rights to sublicense through multiple tiers of sublicenses. These rights are assignable by Assignee.

2. Assistance. Assignor hereby agrees, on its own volition and at Assignee's request and expense, to execute, take all actions and deliver any and all documents, agreements, assignments or transfers necessary or appropriate to perfect or implement this assignment or the rights of the Assignee in the Acquired Intellectual Property. In the event that Assignee is unable for any reason to secure Assignor's signature to any document required to apply for or execute any United States or foreign patent, copyright or other applications with respect to the Acquired Intellectual Property (including improvements, renewals, extensions, continuations, divisions or continuations in part thereof), Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as Assignor's agent and attorney-in-fact to act for and in their behalf, and instead of Assignor, to execute and file any such applications and to do all other lawfully permitted acts to further the perfection, prosecution and issuance of copyrights or other rights therein with the same legal force and effect as if executed by Assignor.

3. Miscellaneous.

3.1 This Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Facsimile signatures will be deemed to be original signatures for all applicable purposes.

3.2 This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware applicable to a contract executed and performed in such state without giving effect to the conflicts of laws principles thereof, except that if it is necessary in any other jurisdiction to have the law of such other jurisdiction govern this Agreement in order for this Agreement to be effective in any respect, then the laws of such other jurisdiction shall govern this Agreement to such extent.

3.3 This Agreement is intended only to affect the assignment of certain assets in accordance with the Asset Purchase Agreement and shall be governed entirely in accordance with the terms and conditions of the Asset Purchase Agreement. In the event of any conflict or ambiguity between the terms hereof and the terms of the Asset Purchase Agreement, the terms of the Asset Purchase Agreement shall govern and be controlling.

3.4 Any term or provision of this Agreement may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a writing signed by the party to be bound thereby. The waiver by a party of any breach hereof for default in the performance hereof shall not be deemed to constitute a waiver of any other default or any succeeding breach or default.

3.5 This Agreement and the other documents delivered in connection with the Asset Purchase Agreement supersede all prior discussions and agreements between the parties with respect to the subject matter hereof, and contain the sole and entire agreement between the parties hereto with respect to the subject matter hereof.

3.6 If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of any party hereto under this Agreement will not be materially affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will

not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in economic and legal effect to such illegal, invalid or unenforceable provision as may be possible.

3.7 Assignor acknowledges that Assignee may assign the Acquired Intellectual Property. The rights and obligations of this Agreement shall inure to the benefit of Assignee, its successors, assigns and other legal representatives, and shall be binding upon Assignor, its successors, legal representatives and assigns.

[Signature Page Follows]


IN WITNESS WHEREOF, the Assignor and Assignee have executed this Acquired Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNOR:

ASSIGNEE:

INTRONN INC.

VIRXSYS CORPORATION

By: 

Peter Donnelly
President and Chief Executive Officer

By: _____

Riku Rautsola
President and Chief Executive Officer

Signature Page to Acquired Intellectual Property Assignment Agreement

IN WITNESS WHEREOF, the Assignor and Assignee have executed this Acquired Intellectual Property Assignment Agreement as of the date first set forth above.

ASSIGNOR:

ASSIGNEE:

INTRONN INC.

VIRXSYS CORPORATION

By: _____
Peter Donnelly
President and Chief Executive Officer

By: 
Riku Rautsola
President and Chief Executive Officer

Signature Page to Acquired Intellectual Property Assignment Agreement

Schedule 2.1
Acquired Assets

See Schedules 2.1(a), 2.1(c) and 2.1(d)

Schedule 2.1(a)
Seller Technologies

See list of patents and patent applications attached hereto as Exhibit 2.1(a).

Trademark application for "SMaRT". See TM Exhibit 2.1(a).

All of the rights, title and interest Seller has in and to the name "Intronn", including any common-law trademark rights.

Schedule 2.1(c)
Wind-Down Costs of Seller

\$25,000.00 to cover various costs for approximately six months following execution of the Asset Purchase Agreement, to be used for, among other things, administration, accounting, taxes, audits, financial statements, closure of accounts, termination of MTAs and contracts, bookkeeping, shareholder support, as-yet un-invoiced expenses, and eventual dissolution of the firm.

Schedule 2.1(d)
Acquired Tangible Assets

1. NU-AIRE Biological safety cabinets – Class II Type A/B3	2
2. NU-AIRE IR-UTOFLOW CO ₂ incubator with Hepa filtration	2
3. Inverted Microscopes	2
4. Bio-Rad iCycler (qPCR machine w/ Dell computer/monitor)	1
5. Bio-Rad MyiCycler (qPCR machine w/ Toshiba laptop computer)	1
6. BioRad PCR machine (base)	1
7. PE Applied bio-system PCR machine	2
8. Eppendorf PCR machine	1
9. Freezer (-80oC)	2
10. Cold box	1
11. UV trans illuminator	2
12. Liquid nitrogen cell storage tank	1
13. Labline shaker (large)	1
14. Flourimeter w/ automatic sample injector (w/ computer+monitor)	1
15. Beckman (DU530) spectrophotometer	1
16. Bio-Rad (SmartSpec 3000) spectrophotometer	1
17. Juan floor centrifuge	1

INTRONN, INC. INDEX OF PATENT APPLICATIONS AND ISSUED PATENTS

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00001 - USE OF SPLICEOSOME MEDIATED RNA TRANS-SPLICING TO CONFER CELL SELECTIVE REPLICATION TO ADENOVIRUSES	INT/ 00001	10/434727	7094399	Granted
INT.00002 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00002	09/756095		Abandoned
INT.00003 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00003	09/838858		Abandoned
INT.00004 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00004	10/076248		Published
INT.00005 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00005	10/075028		Abandoned
INT.00006 - SPLICEOSOME MEDIATED RNA TRANS-SPLICING IN STEM CELLS	INT/ 00006	10/456273		Abandoned
INT.00007 - SCREENING METHOD FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPLICING MOLECULES	INT/ 00007	10/693192		Abandoned
INT.00008 - SCREENING METHOD FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPLICING MOLECULES	INT/ 00008	10/898748		Published
INT.00009 - CORRECTION OF ALPHA-1-ANTITRYPSIN GENETIC DEFECTS USING SPLICEOSOME MEDIATED RNA TRANS SPLICING	INT/ 00009	11/040634		Published

PATENT

REEL: 020074 FRAME: 0145

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00010 - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00010	11/041155		Published
NOTE: NO INT.00011 for TKA, SEE INT.00106-PROV				
INT.00012 - SPLICEOSOME MEDIATED RNA TRANS-SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00012	10/198447		Abandoned
INT.00013 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING IN PLANTS CELLS	INT/ 00013	09/756097		Abandoned
INT.00014 - SPLICEOSOME MEDIATED RNA TRANS-SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00014	10/621867		Abandoned
INT.00015-PROV- USE OF RNA TRANS-SPLICING FOR GENERATION OF INTERFERING RNA MOLECULES	INT/ 00015-PROV	60/600045		Converted
INT.00016-PROV - USE OF SPLICEOSOME MEDIATED RNA TRANS-SPLICING FOR IMMUNOTHERAPY	INT/ 00016-PROV	60/592607		Closed
INT.00017 - METHODS AN COMPOSITIONS FOR USE SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00017	09/133717	6083702	Granted
INT.00018 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00018	09/158863	6280978 B1	Granted
INT.00019 - SPLICEOSOME MEDIATED RNA TRANS-SPLICING FOR CORRECTION OF FACTOR VIII GENETIC DEFECTS	INT/ 00019	10/456153		Abandoned
INT.00020 - PRE-TRANS-SPLICING MOLECULES GENERATED BY TRANS-SPLICING	INT/ 00020	09/087233		Abandoned
INT.00023 - THERAPEUTIC MOLECULES GENERATED BY TRANS-SPLICING	INT/ 00023	08/766354	6013487	Granted
INT.00024 - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00024	09/756096		Abandoned

File Name

INT.00026 - TRANS-SPLICING MEDIATED
PHOTODYNAMIC THERAPY

INT.00027 - SPLICEOSOME MEDIATED RNA TRANS-
SPLICING

INT.00028 - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME-MEDIATED RNA TRANS-SPLICING

INT.00029-CA - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME MEDIATED RNA TRANS-SPLICING

INT.00030-AU - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME-MEDIATED RNA TRANS-SPLICING

INT.00031-EP - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME-MEDIATED RNA TRANS-SPLICING

INT.00032-PCT - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME-MEDIATED RNA TRANS-SPLICING

INT.00033-JP - TRANSGENIC ANIMAL MODEL FOR
SPLICEOSOME-MEDIATED RNA TRANS-SPLICING

INT.00034-EP - SPLICEOSOME MEDIATED RNA TRANS-
SPLICING AND CORRECTION OF FACTOR VIII GENETIC
DEFECTS USING SPLICEOSOME MEDIATED RNA
TRANS-SPLICING

File Index

Client ID / Matter ID	Application No.	Patent No.	Status
INT/ 00026	10/658617		Abandoned
INT/ 00027	10/103294		Abandoned
INT/ 00028	10/136723		Abandoned
INT/ 00029-CA	2485038		Abandoned
INT/ 00030-AU	2003228735		Abandoned
INT/ 00031-EP	3726503		Abandoned
INT/ 00032-PCT	US03/13161		Completed
INT/ 00033-JP	2004-501550		Abandoned
INT/ 00034-EP	3736901.4		Published

All Files

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00035-EP - SPLICEOSOME MEDIATED RNA TRANS- SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00035-EP	3764802.9		Abandoned
INT.00036-EP - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00036-EPC	4077408.5		Abandoned
INT.00037-PCT - CORRECTION OFALPHA-1- ANTITRYPSIN GENETIC DEFECTS USING SPLICEOSOMEMEDIATED RNA TRANS-SPLICING	INT/ 00037-PCT	US05/002549		Abandoned
INT.00038-EP - USE OF SPLICEOSOME MEDIATED RNA TRANS-SPLICING TO CONFER CELL SELECTIVE REPLICATION TO ADENOVIRUSES	INT/ 00038-EP	3810034.3		Published
INT.00039-AU - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION	INT/ 00039-AU	56735/99	773186	Granted
INT.00040-CA - TRANS-SPLICING MEDIATED IMAGING OF GENE EXPRESSION	INT/ 00040-CA	2477295		Pending
INT.00041-CA - SPLICEOSOME MEDIATED RNA TRANS- SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00041-CA	2492469		Abandoned
INT.00042-EP - THERAPEUTIC MOLECULES GENERATED BY TRANS-SPLICING	INT/ 00042-EP	96944760.6	0 883 344	Granted/Val
INT.00043-CA - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00043-CA	2339300		Pending
INT.00044-JP - USE OF SPLICEOSOME MEDIATED RNA TRANS-SPLICING TO CONFER CELL SELECTIVE REPLICATION TO	INT/ 00044-JP	2004-557094		Pending
INT.00045-CA - USE OF SPLICEOSOME MEDIATED RNA USE OF SPLICEOSOME MEDIATED RNA TRANS- SPLICING TO CONFER CELL SELECTIVE REPLICATION TO ADENOVIRUSES	INT/ 00045-CA	2485341		Pending
INT.00046-AU -SPLICEOSOME MEDIATED RNA TRANS- SPLICING TO CONFER CELL SELECTIVE REPLICATION TO ADENOVIRUSES	INT/ 00046-AU	2003302216		Pending
INT.00047-PCT - USE OF SPLICEOSOME MEDIATED RNA TRANS-SPLICING TO CONFER CELL SELECTIVE REPLICATION TOADENOVIRUSES	INT/ 00047-PCT	US03/014804		Completed

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00049-JP - SPLICEOSOME MEDIATED RNA TRANS- SPICING STEM SELLS	INT/ 00049-JP	2004-511476		Published
INT.00050-AU - SPLICESOME MEDIATED RNA TRANS- APLICING IN STEM CELLS	INT/ 00050-AU	2003247505		Pending
INT.00051-CA - SPLICEOSOME MEDIATED RNA TRANS- SPICING STEM SELLS	INT/ 00051-CA	2488249		Pending
INT.00052-PCT - SPLICEOSOME MEDIATED RNA TRANS- SPICING IN STEM SELLS	INT/ 00052-PCT	US03/17954		Completed
INT.00053-JP - METHODS AND COMPOSITIONS FOR USE IN SPLICEOSOME MEDIATED RNA TRANS- SPICING	INT/ 00053-JP	2000-565168		Published
INT.00054-IL -METHOD AND COMPOSITIONS FOR USE IN SPLICESOME MEDIATED RNA TRANS-SPICING	INT/ 00054-IL	141409		Abandoned
INT.00055-CA - SPLICEOSOME MEDIATED RNA TRANS- SPICING	INT/ 00055-CAN	2434118		Pending
INT.00056-EP - SPLICEOSOME MEDIATED RAN TRANS- SPICING	INT/ 00056-EPC	2714709.9		Pending
INT.00057-CA - SCREENING METHOD FOR INDETIFICATION OF EFFICIENT PRE-TRANS-SPICING MOLECULES	INT/ 00057-CA	2503247		Pending
INT.00058-JP - SCREENING METHOD FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPICING MOLECULES	INT/ 00058-JP	547220		Abandoned
INT.00059-EP - SCREENING METHOD FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPICING MOLECULES	INT/ 00059-EPC	3779324.7		Published
INT.00060-PCT - SCREENING METHOD FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPICING MOLECULES	INT/ 00060-PCT	US03/034102		Completed
INT.00061-AU - SCREENING METHODS FOR IDENTIFICATION OF EFFICIENT PRE-TRANS-SPICING MOLECULES	INT/ 00061-AU	2003285009		Pending
INT.00062 - METHODS AND COMPOSITIONS FOR USE SPLICEOSOME MEDIATED RNA TRANS-SPICING	INT/ 00062	09/941492		Abandoned
INT.00063-PCT - THERAPUTIC MOLECULES GENERATED BY TRANS-SPICING	INT/ 00063-PCT	US96/19419		Completed
INT.00064-AU - THERAPEUTIC MOLECULES	INT/ 00064-AU	13299/97	730305	Granted

GENERATED BY TRANS-SPLICING
INT.00065-CA - THERAPEUTIC MOLECULES
GENERATED BY TRANS-SPLICING
INT.00066-JP - THERAPEUTIC MOLECULES
GENERATED BY TRANS-SPLICING
INT.00067-PCT - METHODS AND COMPOSITIONS FOR
USE IN SPLICEOSOME MEDIATED RNA TRANS-
SPLICING
INT.00068-EP - THERAPEUTIC MOLECULES
GENERATED BY TRANS-SPLICING
File Name
INT.00070-AU - SPLICEOSOME MEDIATED RNA TRANS-
SPLICING
INT.00071-EP - SPLICEOSOME MEDIATED RNA TRANS-
SPLICING
INT.00072-IL - METHODS AND COMPOSITIONS FOR USE
IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING
INT.00073-IL - COMPOSITIONS AND METHODS FOR
SPLICEOSOME MEDIATED RNA TRANS-SPLICING
INT.00074-IL - SPLICEOSOME MEDIATED RNA TRANS-
SPLICING
INT.00075-JP - SPLICEOSOME MEDIATED RAN TRANS-
SPLICING
INT.00076-PCT-METHOD AND COMPOSITIONS FOR USE
IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING
INT.00077-AU - METHOD AND COMPOSITIONS FOR USE
IN SPLICEOSOME MEDISTED RNA TRANS-SPLICING
INT.00078-CA - METHOD AND COMPOSITIONS FOR USE
IN SPLICEOSOME MEDIATED RNA TRANS-SPLICING
INT.00079-EPC - METHOD AND COMPOSITIONS FOR
USE SPLICEOSOME MEDIATED RNA TRANS-SPLICING
INT.00080-JP - METHODS AND COMPOSITIONS FOR
USE IN SPLICEOSOME MEDIATED RNA TRANS-SLICING
INT.00081-PCT - TRANS-SPLICING MEDIATED IMAGING
OF GENE EXPRESSION
INT.00082-AU - TRANS-SPLICING MEDIATED IMAGING
OF GENE EXPRESSION

00064-AU
INT/
00065-CA
INT/
00066-JP
INT/
00067-PCT
INT/
00068-EP
INT/
00070-AU
INT/
00071-EP
INT/
00072-IL
INT/
00073-IL
INT/
00074-IL
INT/
00075-JP
INT/
00076-PCT
INT/
INT.00077-AU
INT/
00078-CA
INT/
00079-EPC
INT/
00080-JP
INT/
00081-PCT
INT/
00082-AU

2240494
522848/97
US99/18371
99943690
2002246959
156665
165057
165056
2002-555104
US03/04622
2003215249
2475802
3711065.7
2003-568382
US03/05615
2003213270

Patent No.

Application No.

Client ID /
Matter ID

Status

Pending
Published
Completed
Abandoned
Pending
Pending
Abandoned
Completed
Pending
Pending
Published
Published
Completed
Pending

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00084 - TRANS-SPLICING MEDIOATED IMAGING OF GENE EXPRESSION	INT/ 00084-JP	2003-571427		Published
INT.00085 - TRANS-SPLICING MEDIATED PHOTODYNAMIC THERAPY	INT/ 00085	US04/29022		Abandoned
INT.00086-PCT - SPPLICOSOME MEDIATED RNA TRANS-SPLICING AND CORRECTIONS OF FACTOR VIII GENETIC DEFECTS USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00086	US03/17913		Completed
INT.00087-AU - PLICESOME MEDIATED RNA TRANS-SPLICING AND CORRECTING THE FACTOR VIII GENETIC DEFECTS USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00087	2003237449		Pending
INT.00088-CA - SPPLICOSOME MEDIATED RNA TRANS-SPLICING AND CORRECTING OF FACTOR VIII GENETIC DEFECTS UNSING SPLICOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00088	2488246		Pending
INT.00089-JP - SPPLICOSOME MEDIATED RNA TRANS-SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00089	511472		Published
INT.00090-PCT - SPPLICOSOME MEDIATED RNA TRANS-SPLICING AND CORRECTION OF FACTOR VIII GENETIC DEFECTS USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00090-PCT	US03/022469		Abandoned
INT.00091-AU - SPlicesome mediated RNA TRANS-SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00091	tba		Abandoned
INT.00092-JP - SPLICESOME MEDIATED RNA TRANS-SPLICING FOR CORRECTION OF SKIN DISORDERS	INT/ 00092-JP	2004-521968		Abandoned
INT.00093-EP - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLISEOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00093-EP	US05/002392		Completed

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00094 - SPLICESOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00094-JP	2005-3076		Pending
INT.00096 - EXPRESSION OF APOA1 AND VARIANTS THEREOF USING SPLICESOSOME MEDIATED RNA TRANS-SPLICING	INT/ 00096	11/141447		Published
INT.00097-EP - SPLICESOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00097-EP	Unfiled		Unfiled
INT.00099 - SPLICESOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00099-JP	TBD		Abandoned
INT.00100 - SPLICESOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00100-AU	TBD		Abandoned
INT.00101 - SPLICESOSOME MEDIATED RNA TRANS- SPLICING	INT/ 00101-AU	2004237884		Abandoned
INT.00102 - USE OF SPLICESOSOME MEDIATED RNA TRANS-SPLICEING FOR IMMUNOTHERAPY	INT/ 00102	11/193682		Published
INT.00103 - USE OF RNA TRANS-SPLICING FOR GENERATION OF INTERFERING RNA MOLECULES	INT/ 00103	11/199917		Published
INT.00104 - USE OF RNA TRANS-SPLICING FOR THERAPEUTIC ANTIBODY GENE TRANSFER	INT/ 00104	US05/036215		Completed
INT.00104-AU - USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND POLYPEPTIDE PRODUCTION	INT/ 00104-AU	200702184-3		Pending
INT.00104-CA -USE OF RNA TRANS-SPLICING FOR THERAPEUTIC ANTIBODY GENE TRANSFER	INT/ 00104-CA	TBD		Pending
INT.00104-IN - USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION	INT/ 00104-IN	TBD		Pending
INT.00104-SG-USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION	INT/ 00104-SG	200702184-3		Pending
INT.00104-EP-USE OF RNA TRANS-SPLICING FOR ANTIBODY GENE TRANSFER AND ANTIBODY POLYPEPTIDE PRODUCTION	INT/ 00104-EP	05 815099.6		Pending
INT.00105 - USE OF RNA TRANS-SPLICING FOR THERAPEUTIC ANTIBODY GENE TRANSFER	INT/ 00105	11/245835		Published

PATENT

REEL: 020074 FRAME: 0152

INT.00105-PROV.1 - USE OF RNA TRANS-SPLICING FOR THERAPEUTIC ANTIBODY GENE TRANSFER

INT.00105-PROV.2 USE OF RNA TRANS-SPLICING FOR THERAPEUTIC ANTIBODY GENE TRANSFER

INT.00106-PROV USE OF RNA TRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN VIVO PRODUCTION OF REDUNDANT PROTEINS

INT.00107 - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-AU - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-EP - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-IN - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-JP - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-SG - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT.00107-US - TARGETEDTRANS-SPLICING OF HIGHLY ABUNDANT TRANSCRIPTS FOR IN-VITRO PRODUCTION OF RECOMBINANT PROTEINS

INT/
00105-PROV.1
60/617012
Converted

INT/
00105-PROV.2
60/629821
Converted

INT/
00106-PROV
60/617324
Converted

INT/
00107
05/036424
Completed

INT/
00107-AU
TBD
Pending

INT/
00107-EP
TBD
Pending

INT/
00107-IN
TBD
Pending

INT/
00107-JP
TBD
Pending

INT/
00107-SG
200702185-0
Pending

INT/
00107-US
(00106 in pagestream)
11/245907
Pending

File Name	Client ID / Matter ID	Application No.	Patent No.	Status
INT.00109-CA - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLICESOME MEDIATED RNA TRANS- SPLICING	INT/ 00109-CA	25538285		Pending
INT.00110-EP - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00110-EP	5722539.3		Pending
INT.00111-AU - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00111-AU	2005207053		Pending
INT.00112-JP - EXPRESSION OF APOA-1 AND VARIANTS THEREOF USING SPLICESOME MEDIATED RNA TRANS-SPLICING	INT/ 00112-JP	2006-551416		Pending
INT.00113-CA - SPLICESOME MEDIATED RNA TRANS- SPLICING	INT/ 00113-CA	2558640		Abandoned (Maintenance)

149

Total Number of Files Displayed:

RECORDED: 11/06/2007

Printed by Administrator on Tue, Jul 10, 2007

**PATENT
REEL: 020074 FRAME: 0156**